Haemonetics (NYSE:HAE) Given Outperform Rating at Barrington Research

Barrington Research reiterated their outperform rating on shares of Haemonetics (NYSE:HAE) in a report published on Wednesday, Briefing.com Automated Import reports. They currently have a $139.00 price objective on the medical instruments supplier’s stock, up from their previous price objective of $116.00. Barrington Research also issued estimates for Haemonetics’ Q3 2020 earnings at $0.79 EPS, Q4 2020 earnings at $0.77 EPS, FY2020 earnings at $3.05 EPS, Q1 2021 earnings at $0.79 EPS, Q2 2021 earnings at $0.82 EPS, Q3 2021 earnings at $0.95 EPS, Q4 2021 earnings at $0.94 EPS and FY2021 earnings at $3.50 EPS.

A number of other equities research analysts have also issued reports on the stock. Morgan Stanley boosted their price target on shares of Haemonetics from $128.00 to $148.00 and gave the company an overweight rating in a report on Wednesday. Zacks Investment Research upgraded shares of Haemonetics from a sell rating to a hold rating in a research note on Tuesday, April 9th. Jefferies Financial Group upped their price objective on shares of Haemonetics from $125.00 to $140.00 and gave the company a buy rating in a research note on Friday, August 2nd. Raymond James upped their price objective on shares of Haemonetics from $110.00 to $150.00 and gave the company an outperform rating in a research note on Wednesday. Finally, TheStreet upgraded shares of Haemonetics from a c+ rating to a b- rating in a research note on Tuesday, May 7th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. The company currently has a consensus rating of Buy and an average target price of $140.67.

Shares of HAE stock traded down $1.07 during trading hours on Wednesday, reaching $133.03. 257,452 shares of the stock traded hands, compared to its average volume of 353,451. Haemonetics has a 1-year low of $80.24 and a 1-year high of $135.28. The firm has a fifty day moving average of $121.98. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.10 and a quick ratio of 1.62. The firm has a market capitalization of $6.64 billion, a price-to-earnings ratio of 55.66, a PEG ratio of 3.18 and a beta of 0.82.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Tuesday, August 6th. The medical instruments supplier reported $0.81 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.63 by $0.18. Haemonetics had a net margin of 5.05% and a return on equity of 21.07%. The business had revenue of $238.50 million for the quarter, compared to analyst estimates of $236.82 million. During the same quarter in the previous year, the business earned $0.59 earnings per share. The firm’s revenue was up 4.0% compared to the same quarter last year. As a group, analysts forecast that Haemonetics will post 3.03 earnings per share for the current year.

In other news, CEO Christopher Simon sold 57,587 shares of the stock in a transaction on Monday, May 13th. The shares were sold at an average price of $94.51, for a total transaction of $5,442,547.37. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Dan Goldstein sold 1,107 shares of the stock in a transaction on Thursday, June 6th. The stock was sold at an average price of $103.25, for a total transaction of $114,297.75. The disclosure for this sale can be found here. In the last quarter, insiders sold 105,754 shares of company stock worth $10,455,709. Company insiders own 1.32% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in HAE. Squarepoint Ops LLC purchased a new stake in shares of Haemonetics in the fourth quarter valued at approximately $203,000. Geode Capital Management LLC grew its position in shares of Haemonetics by 4.5% in the fourth quarter. Geode Capital Management LLC now owns 628,695 shares of the medical instruments supplier’s stock valued at $62,900,000 after purchasing an additional 27,344 shares in the last quarter. Cardinal Capital Management grew its position in shares of Haemonetics by 2.0% in the first quarter. Cardinal Capital Management now owns 8,260 shares of the medical instruments supplier’s stock valued at $722,000 after purchasing an additional 160 shares in the last quarter. First Citizens Bank & Trust Co. grew its position in shares of Haemonetics by 37.7% in the first quarter. First Citizens Bank & Trust Co. now owns 3,160 shares of the medical instruments supplier’s stock valued at $276,000 after purchasing an additional 865 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV purchased a new stake in shares of Haemonetics in the first quarter valued at approximately $203,000. Institutional investors own 98.53% of the company’s stock.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Further Reading: 52-Week High/Low

Analyst Recommendations for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.